Literature DB >> 12736496

Antioxidant effects in the quinone fraction from Auxemma oncocalyx TAUB.

Maria Augusta Drago Ferreira1, Osmar Del Rio Holanda Nunes, Luzia Kalyne Almeida Moreira Leal, Otília Deusdenia Loiola Pessoa, Telma Leda Gomes De Lemos, Glauce Socorro de Barros Viana.   

Abstract

In previous studies in vitro we showed that the quinone fraction (QF) from the heartwood of Auxemma oncocalyx TAUB. presented antiplatelet and antioxidant activities. In the present work, the QF antioxidant property was evaluated in models of CCl(4)-induced hepatotoxicity in rats, and prolongation of pentobarbital-induced sleeping time in mice. Our results showed that levels of plasma glutamate-pyruvate-transaminase (GPT), as well as glutamate-oxalate-transaminase (GOT), were increased by the administration of CCl(4). On the other hand, only GPT levels were reduced by the QF treatment. Pentobarbital sleeping time was prolonged by the administration of CCl(4) and reduced by the QF treatment. Moreover, QF did not alter the pentobarbital-induced sleeping time. In conclusion, we showed that QF, represented mainly by oncocalyxone A, has hepatoprotective activity, and this effect is at least in part due to the antioxidant activity of this quinone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736496     DOI: 10.1248/bpb.26.595

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.

Authors:  M A D Ferreira; N R F do Nascimento; C M de Sousa; O D L Pessoa; T L G de Lemos; J S Ventura; M Schattner; A M Chudzinski-Tavassi
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

2.  Oncocalyxone A functions as an anti-glycation agent in vitro.

Authors:  Ingrid Sofia Vieira de Melo; Aldenir Feitosa Dos Santos; Telma Leda Gomes de Lemos; Marília Oliveira Fonseca Goulart; Antônio Euzébio Goulart Santana
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.